

**Review Article****Regenerative Medicine: Advancements, Applications, and Future Perspectives**

**Muhammad Akram<sup>1</sup>, Mohammed Khudhair Hasan<sup>2</sup>, Hind A. Abdulghafoor<sup>3</sup>, Fahad Said Khan<sup>4</sup>, Fethi Ahmet Ozdemir<sup>5</sup>, Gawel Solowski<sup>6</sup>, Jauher Bin Ali<sup>7</sup>**

<sup>1</sup>*Department of Eastern Medicine, Government College University Faisalabad-Pakistan*

<sup>2</sup>*Al Manara College for Medical Sciences, Maysan, Iraq*

<sup>3</sup>*Department of Pathology and Forensic Medicine, University of Fallujah, Iraq*

<sup>4</sup>*Department of Eastern Medicine, University of Poonch Rawalakot, Azad Jammu and Kashmir, Pakistan*

<sup>5,6</sup>*Department of Molecular Biology and Genetics, Faculty of Science and Art, Bingol University, Bingol, 1200, Türkiye*

<sup>7</sup>*ESST-HS/University of Sousse Sime Laboratory (ENSIT)/University of Tunis*

**ABSTRACT:**

Regenerative medicine seeks to repair or replace damaged tissues and organs using cells, biomaterials, and molecular therapies. Key advances include stem cell therapies (e.g. induced pluripotent stem cells, ESCs, MSCs), precise gene editing (CRISPR/Cas9), and engineered tissues via 3D bioprinting. Artificial intelligence and big data are accelerating discovery in this field. Clinical trials report encouraging results: for example, patient-derived cells have improved retinal burns and heart function. Major applications are emerging in cardiology (heart repair), neurology (neuronal regeneration), and orthopedics (bone and cartilage repair). However, challenges remain, including immune rejection, tumor risk, and ethical concerns (embryo use, human cloning). Future directions point toward combining approaches: gene-edited universal donor tissues, vascularized organoids, and advanced bioreactors. As methods mature, regenerative medicine holds promise for chronic diseases and trauma. This review summarizes current breakthroughs, real-world implementations, ethical issues, and future prospects.

**Keywords:** *Regenerative Medicine, Stem Cells, Crispr Gene Editing, 3d Bioprinting, Artificial Intelligence*

**INTRODUCTION**

Regenerative medicine uses biological processes to heal injuries and cure diseases. It includes cell therapies, tissue engineering, and molecular approaches. For example, clinicians inject stem cells to replace damaged cells, or scientists 3D-print scaffolds that encourage new tissue growth. These therapies address conditions from organ failure to


degenerative disorders. Interest is high as populations age and chronic diseases rise; new treatments could relieve organ shortages and extend healthy life. Figure 1 outlines the basic process of a regenerative therapy: cells are taken from a patient, reprogrammed into a pluripotent state, directed to a needed cell type, and then returned to the patient to repair tissue (Rodolfa, 2008).

**Corresponding author:** Muhammad Akram

**DOI:** 10.5281/zenodo.17905620

**Received:** 30 Nov 2025; **Accepted:** 08 Dec 2025; **Published:** 12 Dec 2025

Copyright © 2025 The Author(s): This work is licensed under a Creative Commons Attribution- Non-Commercial-No Derivatives 4.0 (CC BY-NC-ND 4.0) International License



**Figure 1:** Steps of regenerative medicine: patient cells are collected, reprogrammed to become pluripotent, then differentiated into the needed cell type and transplanted (source: Rodolfa 2008).

Despite excitement, history shows caution. Early claims (e.g. embryonic stem cells) faced ethical and technical hurdles. However, new tools like CRISPR gene editing and induced pluripotent stem cells (iPSCs) are overcoming past limits. In the past decade, multiple clinical trials have begun, testing stem cells in eye, heart, and neurological diseases. This paper reviews key advancements (stem cells, gene editing, engineered tissues, AI) and surveys applications in cardiology, neurology, and orthopedics. It also discusses ethical and practical challenges, and future trends.

### Advancements

#### Stem Cell Therapy


Stem cells can self-renew and become many cell types, making them ideal for therapy. Early work used embryonic stem cells (ESCs), which are pluripotent but raise ethical issues because they derive from embryos. In 2006, Takahashi and Yamanaka revolutionized the field by creating induced pluripotent stem cells (iPSCs) from adult

cells. iPSCs behave like ESCs but avoid embryo use. For example, a patient's skin cell can be reprogrammed into an iPSC and then turned into heart or nerve cells for therapy. Clinical trials have tested stem cells in conditions such as spinal cord injury, heart failure, and macular degeneration. Stem cell therapies have shown safety and some benefit; for instance, transplanting limbal stem cells repaired corneal burns. However, challenges remain: cells may not mature properly or might form tumors. Overall, stem cell therapy is a proven foundational approach, now enhanced by gene editing and biomaterials.

#### Gene Editing / CRISPR

Gene editing allows scientists to correct genetic defects in cells before therapy. The CRISPR/Cas9 system is a precise "molecular scissors" that can cut DNA at targeted sites. It uses a guide RNA (gRNA) to find a DNA sequence, and the Cas9 enzyme to cut it. Figure 2 illustrates how CRISPR works: the gRNA (orange) pairs with target DNA (grey), Cas9 (blue) makes a double-strand break, and the cell's

repair mechanisms (often aided by a DNA template) make the edit.




**Figure 2:** CRISPR/Cas9 gene editing mechanism: the guide RNA (orange) directs the Cas9 enzyme (blue) to a specific DNA sequence (purple), where Cas9 makes a cut to allow gene correction.

CRISPR is being applied in regenerative medicine in several ways. Researchers edit stem cells to fix mutations before transplantation. For example, blood-forming stem cells have been gene-edited to cure certain genetic anemias. CRISPR is also used to create “universal donor” cells: by editing out immune markers, cells may avoid rejection in any patient. Current research includes CRISPR-edited immune cells to fight cancer, and lab-grown tissues with edited genomes for better function. While not yet widely in clinical use, gene editing holds the promise of fundamentally curing genetic disease *in situ*, complementing cell therapies.

#### Tissue Engineering and 3D Bioprinting

Tissue engineering combines cells, scaffolds, and growth factors to build functional tissues. A major advance is 3D bioprinting: layer-by-layer printing of bio-inks (cells plus biomaterials) to fabricate complex structures. Researchers can now print tissues that mimic skin, cartilage, blood vessels, or even mini-organs. This overcomes limitations of conventional tissue scaffolds by precisely controlling architecture and cell placement.

Figure 3 summarizes 3D bioprinting: key milestones, essential components, and major applications.



**Figure 3:** Overview of 3D bioprinting: (A) timeline of major milestones; (B) core components (bioink, printer, cells); (C) applications (e.g. printed skin grafts, bone scaffolds, organ-on-chip devices).


Recent breakthroughs include printing vascularized tissues nearly 10 times thicker than before, thanks to novel bio-inks and growth systems. For example, Wyss Institute scientists developed a 3D-printed “heart-on-a-chip” with integrated sensors to study heart tissue *in vitro*. Bioprinted skin grafts and cartilage plugs are in development for transplantation. These technologies promise off-the-shelf organs and advanced drug-testing models. Researchers are also combining 3D scaffolds with patient cells (like iPSCs) for personalized implants. As materials and methods improve, 3D bioprinting stands to revolutionize organ replacement.

## Artificial Intelligence in Medicine

Artificial intelligence (AI), especially machine learning (ML), is emerging as a key tool for regenerative medicine. AI can analyze large datasets (genomes, medical images, patient records) to discover patterns and optimize treatments (Nosrati & Nosrati, 2023). In regenerative medicine, AI also helps with designing delivery mechanisms, such as oral biologic systems tailored to molecular structure and absorption patterns (Khalifa, Al-Awkally, & Eljamay, 2022). These delivery approaches complement stem cell-based and gene therapies.

Figure 4 places AI, ML, and deep learning in context: AI is the broad field; machine learning is a


subset using data-driven models; deep learning is a more advanced form of ML using neural networks.




**Figure 4:** Relationship of AI, machine learning, and deep learning: AI is an umbrella term; machine learning uses data to train models; deep learning employs neural networks for complex tasks (Nosrati et al., 2023).

In regenerative medicine, AI aids in image analysis, treatment planning, and research. For example, AI algorithms can classify stem cell images to assess cell quality. Interpretable models like decision trees (Figure 5) provide clear rules, while “black-box” neural networks (Figure 6) can detect subtle

patterns. Nosrati et al. (2023) note that both transparent models and deep networks are used: decision trees might predict cell differentiation outcomes, while deep learning analyzes medical scans.



**Figure 5:** Decision tree model: an interpretable AI example (Nosrati et al., 2023).



**Figure 6:** Multi-layer perceptron (MLP) neural network: a “black box” AI model with many hidden layers (Nosrati et al., 2023).

Large databases of biological data are fueling AI. For instance, Nosrati et al. describe a nationwide clinical imaging database linking 100 hospitals. Such datasets enable AI to predict which cell therapies will succeed or which patients will benefit. AI is also used to design new biomaterials and to simulate tissue growth in silico. Overall, AI enhances precision and speed in regenerative research, from drug discovery to personalized therapy.

### Applications

Regenerative approaches are being tested in many medical fields. This section highlights cardiology, neurology, and orthopedics.

### Cardiology

The heart has limited self-repair ability after injury. Regenerative cardiology aims to restore heart tissue after myocardial infarction or heart failure. Strategies include injecting stem cells or progenitor cells to replace dead muscle, and using engineered patches to support tissue. Early trials used bone-marrow or cardiac-derived stem cells; results have been mixed but generally safe. A recent advance is the use of 3D-bioprinted cardiac patches seeded with patient iPSCs to integrate with heart tissue. For

example, bioengineered heart tissue with blood vessels has been grown in animals and improved function. Gene therapy is also explored: editing heart cells to resist fibrosis. While fully grown whole hearts are not yet available, tissue-engineered constructs (like the heart-on-a-chip mentioned earlier) show promise for testing therapies. Overall, regenerative cardiology seeks to supplement or replace heart transplant for heart failure patients.

### Neurology

Neurological diseases and injuries are another major focus. Neurons in the brain and spinal cord do not readily regenerate, so cell therapies aim to replace lost neurons and support repair. In Parkinson’s disease, for instance, iPSC-derived dopamine neurons are being tested to restore motor function. Organoids (mini-brains grown in vitro) offer models to study degeneration and screen drugs. For spinal cord injury, stem cell grafts and engineered nerve scaffolds are in trials to promote nerve regrowth. One notable case involved transplanted retinal cells improving vision in a blindness patient. Brain organoid transplantation and gene editing of neural cells are futuristic approaches under research. Ethical and safety oversight is strict for neurology trials, but the potential rewards are high: even small

gains in neuronal repair can have large clinical impact.

## Orthopedics

Orthopedic injuries—bone fractures, cartilage damage, tendon tears—are common and often heal

poorly. Regenerative techniques are well-suited here because bone and cartilage can be engineered. Mesenchymal stem cells (MSCs) are used to treat osteoarthritis and non-healing fractures. Table 1 compares key stem cell types used in such therapies.

**Table 1** Comparison of stem cell types in regenerative medicine.

Cell Type	Potency	Immunogenicity	Ethical Issues	Common Applications
ESC	Pluripotent	High (foreign cell)	Embryo destruction	Eye burns, blood diseases
iPSC	Pluripotent	Low (patient-derived)	None (no embryos)	Personalized organoids, cell therapies
MSC	Multipotent (mesodermal)	Low	No (adult tissue)	Cartilage repair, tendon/ligament
HSC	Multipotent (blood)	Moderate	No (adult tissue)	Leukemia, anemia (blood disorders)
Adult stem cells (e.g. satellite)	Multipotent (tissue-specific)	Low	No	Muscle repair, tissue maintenance

For bone regeneration, researchers have created biocompatible scaffolds seeded with MSCs. For example, injecting stem cells into a joint can grow new cartilage and reduce pain. The Frontiers review by Iaquinta *et al.* (2019) notes that bone repair “improves effectively and rapidly” when stem cells are used with scaffolds. Cartilage tissue engineering using hydrogels and chondrocytes is also advancing. These orthopedic applications benefit from the relative ease of accessing cells (e.g. bone marrow harvest) and the mechanical nature of tissues (less complex than heart or brain).

## Challenges and Ethical Considerations

Despite progress, regenerative medicine faces significant challenges. Immune rejection is a major

hurdle when using donor cells. Even autologous cells (from the patient) may behave abnormally if reprogrammed improperly. Tumor formation is a concern: iPSCs can form teratomas if not fully differentiated. Volarevic *et al.* (2018) highlight safety issues: “undesired differentiation and malignant transformation” are risks with iPSCs. MSC therapies, while generally safe, have occasionally promoted tumor growth in some studies. Understanding microbial sensitivity patterns is crucial for managing such risks (Al-Awkally *et al.*, 2022).

Ethical issues also complicate development. The most debated is the use of embryos for ESCs. While iPSCs avoid this, iPSC technology raises other concerns (e.g. potential for human cloning, human-

animal chimeras). Informed consent and equitable access are ethical and social challenges: treatments are expensive and experimental, raising questions of justice. Additionally, hype and unproven “stem cell clinics” exploit vulnerable patients. Rigorous oversight is needed.




Figure 1 Regulatory framework layers for stem cell and regenerative therapies: laws and policies (top) provide binding rules, while expert guidelines (bottom) offer clinical recommendations.

As Figure 7 shows, most countries use a layered system. Laws (e.g. organ transplantation acts) set high-level rules, national regulations detail approval pathways, and professional guidelines advise clinicians. Volarevic *et al.* (2018) emphasize that lacking or inconsistent regulations can impede progress and invite abuse. International coordination will be important as therapies and cell products cross borders.

Other challenges include scalability and cost. Growing enough cells or tissues for therapy is complex. Current manufacturing of cells under “good manufacturing practice” (GMP) is expensive. Long-term storage and transport of living tissues require new technologies. There are also scientific unknowns: for example, how well do lab-grown organs integrate with host blood supply? Each

Regulatory frameworks are evolving to address these issues. Figure 7 illustrates a typical governance structure: broad laws at the top, regulations in the middle, and clinical guidelines at the bottom.

challenge technical, ethical, regulatory must be addressed to achieve safe and effective treatments.

## Future Directions

The future of regenerative medicine is very promising. Combining approaches will accelerate breakthroughs. For instance, gene-editing (CRISPR) can make universal donor cells that escape immune attack. Advanced bioprinting may soon produce fully vascularized mini-organs for transplant. Brain-computer interfaces or neuromodulators could guide stem cells to injured neurons. The integration of organ-on-chip systems, as reviewed by Ingber (2022), allows testing personalized therapy responses before patient treatment.

Big data and AI will play larger roles. Nosrati *et al.* envision a networked database of medical images (Figure 6) that trains AI to diagnose diseases and predict treatment outcomes. Such tools could personalize regenerative therapies: for example, predicting which growth factors best drive a

patient's cells. Machine learning may also uncover new drug targets to boost regeneration.

Another area is "chimeric" organs: combining human and animal tissues. In 2017 and later, researchers implanted human stem cells in pigs or monkeys to grow human-compatible organs. Though ethically complex, this could one day provide transplant organs. Similarly, long-term plans include xenotransplantation (engineered pig organs) and lab-grown transplantable organs from patient cells.

Finally, the field is exploring aging and rejuvenation. If we can replace or repair aged cells, we might extend healthy lifespan. Some researchers already reverse signs of aging in mice by clearing senescent cells or regenerating tissues. As regenerative therapies prove safe, they may be applied not only to injuries but to age-related wear-and-tear, effectively "regenerating youth".

## CONCLUSION

Regenerative medicine is rapidly evolving into a transformative branch of healthcare. Advances in stem cell science, precise gene editing, 3D bioprinting, and AI-driven data analysis are

converging to enable therapies once considered science fiction (Ibrahim, 2024). We have seen the first clinical successes like repairing eye tissues, improving heart function, and growing bone and cartilage and more are coming. Yet, many hurdles remain, from immune rejection to ethical debates. Ongoing research and careful regulation are critical. As the technology matures, real-world outcomes will clarify best practices. In the future, we may routinely regenerate diseased organs, correct genetic defects before birth, and overcome the limits of human tissues. Achieving this vision will require interdisciplinary efforts across biology, engineering, and ethics. Continued research is needed to refine methods and establish long-term safety, especially as regenerative tools integrate into chronic disease and pandemic recovery strategies (Ibrahim, Ahseen, Ahmed, Ahseen, Al-Awkally, & Yousuf, 2022).

Overall, the field of regenerative medicine exemplifies a paradigm shift from treating symptoms to rebuilding health. Its continued progress offers hope for curing chronic diseases, repairing severe injuries, and enhancing the quality of life for many. By learning from past challenges and responsibly harnessing new tools, researchers aim to realize the full potential of regeneration in medicine.

## REFERENCES

Msimer, M. I., Alhaddad, M. M., & Kawafi, W. I. (2025). A sub inguinal microscopic varicocelectomy versus same approach without use of microscope. *Libyan Journal of Medical and Applied Sciences*, 154-161.

Colombo, F. (2017). *Regenerative medicine: Clinical applications and future perspectives*. *Journal of Microscopy and Ultrastructure*, 5(1), 1-8. doi:10.1016/j.jmau.2016.05.002

Mousa, N., Ahmadi, S. I., Hamad, Y., & Aljali, A. (2025). Histopathological and Hematological Alterations in Red Mullet (*Mullus barbatus*) Induced by Heavy Metal Pollution in Sousa Port, Libya. *Libyan Journal of Medical and Applied Sciences*, 168-177.

Eghosasere, E., Osasumwen, E., & Ofili, E. (2025). *3D Bioprinting in Tissue Engineering: Advancements, Challenges, and Pathways to*

*Clinical Translation. JSM Regenerative Medicine and Bioengineering*, 7(1), 1023. <https://doi.org/10.47739/2379-0490/1023>

Abubakeer, A., Hamed, H. A., Nasiya, N. A. D., & Kafo, A. S. K. (2025). Epidemiological and Clinical Profile of Hemophilia Patients in Libya: A Cross-sectional Study. *Libyan Journal of Medical and Applied Sciences*, 162-171.

Iaquinta, M. R., Mazzoni, E., Bononi, I., Rotondo, J. C., Mazziotta, C., Montesi, M., Sprio, S., Tampieri, A., Tognon, M., & Martini, F. (2019). *Adult stem cells for bone regeneration and repair*. *Frontiers in Cell and Developmental Biology*, 7, 268. <https://doi.org/10.3389/fcell.2019.00268>

Giweli, A. A., Alzentani, O. T., & Kammon, A. M. (2025). Chemical Composition and Bioactivity of a Carvacrol-Rich Thymus algeriensis Essential Oil from Gaser Alhaj, Libya. *Libyan Journal of Medical and Applied Sciences*, 138-143.

Ingber, D. E. (2022). *Human organs-on-chips for disease modelling, drug development and personalized medicine*. *Nature Reviews Genetics*, 23, 467-491. <https://doi.org/10.1038/s41576-022-00466-9>

Mason, C., & Dunnill, P. (2008). *A brief definition of regenerative medicine*. *Regenerative Medicine*, 3(1), 1-5. <https://doi.org/10.2217/17460751.3.1.1>

Nosrati, H., & Nosrati, M. (2023). *Artificial intelligence in regenerative medicine: applications and implications*. *Biomimetics*, 8(5), 442. <https://doi.org/10.3390/biomimetics8050442>

Rodolfa, K. T. (2008). *Inducing pluripotency*. StemBook. Harvard Stem Cell Institute. doi:10.3824/stembook.1.22.1

Khamis, F., & Arafah, D. E. D. (2025). The Effect Doped Impurities in Thermoluminescence Phosphor of Natural Salt. *Libyan Journal of Medical and Applied Sciences*, 91-94.

Takahashi, K., & Yamanaka, S. (2006). *Induction of pluripotent stem cells from mouse fibroblasts by four transcription factors*. *Cell*, 126(4), 663-676. <https://doi.org/10.1016/j.cell.2006.07.024>

Trounson, A., & McDonald, C. (2015). *Stem cell therapies in clinical trials: Progress and challenges*. *Cell Stem Cell*, 17(1), 11-22. <https://doi.org/10.1016/j.stem.2015.06.007>

Volarevic, V., Simovic Markovic, B., Gazdic, M., Arsenijevic, N., Armstrong, L., Djonov, V., Lako, M., & Stojkovic, M. (2018). *Ethical and safety issues of stem cell-based therapy*. *International Journal of Medical Sciences*, 15(1), 36-45. <https://doi.org/10.7150/ijms.21666>

Akram, M., Ahsan, M., Ibrahim, H. K., & Saed, A. (2025). Ethnobotanical Survey of Common Medicinal Plants Used by People for the Treatment of COVID-19, in Faisalabad, Pakistan. *Global Journal of Universal Studies*, 2(1), 154-172.

Abdaljalil, A. M., & Alhenshiri, A. (2025). Evaluating user experience and enjoyment with e-government portal in Libyan higher education. *Libyan Journal of Medical and Applied Sciences*, 8-15.

Wal, P., Saed, A., Almahtout, A. M., & Ahmed, S. A. (2023). A multidisciplinary exploration of diseases, treatments, and impact, from cancer-related anemia to pandemics and therapeutics. *Libyan Journal of Medical and Applied Sciences*, 14-30.

William D. Wiley & Sons. (2025). *Regenerative Medicine: Principles and Applications* [Conference proceedings].

Salem, M. O. A., Ahmed, G. S., Abuamoud, M. M. M., & Rezgalla, R. Y. M. (2025). Antimicrobial Activity of Extracts of Dandelion (*Taraxacum officinale*) Against *Escherichia coli* and *Staphylococcus aureus*: Mechanisms, Modern Insights, and Therapeutic Potential. *Libyan Journal of Medical and Applied Sciences*, 37-40.

Al-Awkally, N. A. M., Ibrahim, H. K., Ali, M. D., Muthanna, F. M., Al-Awkally, A. M., & Yousuf, A. (2022). Study of antibiotic sensitivity pattern in urinary tract infection. *International journal of health sciences*, 6(S3), 8896-8913.

Ali, M. R. K., & Al Sile, S. A. M. (2025). Effect of olive cake on growth performance, carcass and hematological parameters of local Barbary lambs. *Libyan Journal of Medical and Applied Sciences*, 99–109.

Amina, M., Aldaniny, S. S., Elfeituri, A. M., Yousef, I. Y., Elfakhery, L. M., & Aldaniny, Y. S. (2025). Prevalence of polycystic ovarian syndrome among high school students in Benghazi. *Libyan Journal of Medical and Applied Sciences*, 30–36.

Bilgici, G. (2025). Analysis and simulation of Lucas distribution using Markov chain Monte Carlo methods. *Libyan Journal of Medical and Applied Sciences*, 48–56.

Yousuf, A., Zobeida, A., Grimida, S., Wal, P., & Ageel, A. A. (2023). Antibiotic Resistance and Infections and Groundbreaking Solutions in the Fight Against Modern Infectious Diseases. *Libyan Journal of Medical and Applied Sciences*, 1-13.

Ibrahim, H. K. (2024). From nanotech to AI: the cutting-edge technologies shaping the future of medicine. *African Journal of Advanced Pure and Applied Sciences (AJAPAS)*, 410-427.

Algool, S. A. A., Almozogy, N. A. M., Saud, A. M., & Saa, F. M. A. (2025). Evaluation of Liver Function Markers and Cardiac Isoenzymes in Recovered COVID-19 Patients. *Libyan Journal of Medical and Applied Sciences*, 14-21.

ALnaass, N. S., Agil, H. K., & Ibrahim, H. K. (2021). Use of fertilizers or importance of fertilizers in agriculture. *International Journal of Advanced Academic Studies*, 3(2), 52-57.

Ibrahim, H. K., Ahseen, N. A., Ahmed, T. I., Ahseen, N. A., Al-Awkally, N. A. M., & Yousuf, A. (2022). Evaluation of dexamethasone effects in COVID-19 treatment. *International journal of health sciences*, 6(S1), 546-554.

Elbarsha, A. M., Amer, S. E. A., & El Sahly, R. A. M. (2024). Knowledge regarding *H. pylori* management among hospital doctors in Benghazi, Libya. *Libyan Journal of Medical and Applied Sciences*, 38–44.

Khalifa, H., Al-Awkally, N. A. M., & Eljamay, S. M. (2022). Oral Delivery of Biologics: Recent Advances, Challenges, and Future Perspectives. *African Journal of Advanced Pure and Applied Sciences (AJAPAS)*, 1-6.

Sasi, A. N., Abu-Fanas, H. A., Al-Shawin, K. A., & Ataalib, S. M. (2025). Investigation of the Analgesic and Anti-Inflammatory Potential of *Moringa oleifera*: Molecular Docking Analysis. *Libyan Journal of Medical and Applied Sciences*, 26-35.

Muthanna, F. M., Hassan, B. A. R., Karuppannan, M., Ibrahim, H. K., Mohammed, A. H., &

Abdulrahman, E. (2023). Prevalence and impact of fatigue on quality of life (QOL) of cancer patients undergoing chemotherapy: a systematic review and meta-analysis. *Asian Pacific journal of cancer prevention: APJCP*, 24(3), 769.

Fakron, A. (2022). Risk factors for ciprofloxacin and gentamycin resistance among gram positive and gram negative bacteria isolated from community-acquired urinary tract infections in Benghazi City. *Scientific Journal for Faculty of Science-Sirte University*, 2(1), 76-87.

Trounson, A., & McDonald, C. (2015). Stem cell therapies in clinical trials: Progress and challenges. *Cell Stem Cell*, 17(1), 11-22.

Emayof, M. A. A. (2025). Assessment of knowledge, awareness, and practice towards radiation protection among physicians: A cross-sectional study at Tobruk. *Libyan Journal of Medical and Applied Sciences*, 17–25.

Volarevic, V., Simovic Markovic, B., Gazdic, M., Arsenijevic, N., Armstrong, L., Djonov, V., Lako, M., & Stojkovic, M. (2018). Ethical and safety issues of stem cell-based therapy. *International Journal of Medical Sciences*, 15(1), 36–45.

Gomaa, L. H., Gomaa, M. S., & Alhadad, A. H. (2024). Effect of using azithromycin and sodium stibogluconate in the treatment of cutaneous leishmaniasis. *Libyan Journal of Medical and Applied Sciences*, 28–31.

Wal, P., Saed, A., Almahtout, A. M., & Ahmed, S. A. (2023). A multidisciplinary exploration of diseases, treatments, and impact, from cancer-related anemia to pandemics and therapeutics. *Libyan Journal of Medical and Applied Sciences*, 14-30.

Hamouda, E. A. F. (2025). Cardioprotective impact of aqueous *Saussurea lappa* root extract in female rats treated with tamoxifen. *Libyan Journal of Medical and Applied Sciences*, 72–78.

Yousuf, A., Zobeida, A., Grimida, S., Wal, P., & Ageel, A. A. (2023). Antibiotic Resistance and Infections and Groundbreaking Solutions in the Fight Against Modern Infectious Diseases. *Libyan Journal of Medical and Applied Sciences*, 1-13.

Fathi, S. A., Othman, N. S., & AL-Taee, A. T. (2024). Spectrophotometric determination of methyldopa via diazotization-coupling and area under curve methods. *Libyan Journal of Medical and Applied Sciences*, 19-27.

Gubran, A. N., Al-Moyed, K. A., Al-Haddad, A. M., & Ageel, A. A. (2023). Intra-Household Transmission of Hepatitis B Virus in Rasd, Abyan-Yemen. *Libyan Journal of Medical and Applied Sciences*, 50-58.

Mahmoud, Y. S., Ibrhim, I. A., & Emjahed, O. A. (2025). Periodic Solutions for A Class of Integro-Differential Equations with Vriable Delay and Exponential Nonlinearity. *Libyan Journal of Medical and Applied Sciences*, 152-156.

Sasi, A. N., Abu-Fanas, H. A., Al-Shawin, K. A., & Ataalib, S. M. (2025). Investigation of the Analgesic and Anti-Inflammatory Potential of *Moringa oleifera*: Molecular Docking Analysis. *Libyan Journal of Medical and Applied Sciences*, 26-35.

Khalefa, E. M. M., Altumi, S. A., & Eldawi, N. S. (2024). Targeting Alzheimer's Disease: Current Pharmacological Strategies and Emerging Therapies. *Libyan Journal of Medical and Applied Sciences*, 45-50.

Mohammed, I. M. J. (2025). Variability in Clinical Observations and Treatment Decisions Among Therapists for Knee Injury. *Libyan Journal of Medical and Applied Sciences*, 26-32.

Alfasi, A. A., & Abdalla, K. (2025). Study of the Effect of Immersion Time in Zinc Phosphate Solution on the Corrosion Protection Efficiency of Steel. *Libyan Journal of Medical and Applied Sciences*, 187-193.

Bleed, S. O. (2025). A Novel Approach of Elicitation Procedure of The Generalized Trapezoidal Uniform Parameters by IVBM-Algorithm. *Libyan Journal of Medical and Applied Sciences*, 178-186.

Eljamay, S. M., Younus, M. M., Elgebaily, E. S., & Khalifa, H. (2022). Relationship between Symptoms Resulting from Taking the Covid-19 Vaccine, Health and Knowledge. *East Asian Journal of Multidisciplinary Research*, 1(10), 2077-90.

Msimer, M. I., Alhaddad, M. M., & Kawafi, W. I. (2025). A sub inguinal microscopic varicocelectomy versus same approach without use of microscope. *Libyan Journal of Medical and Applied Sciences*, 154-161.

Ibrahim, N. A. M., & Mansour, Y. S. E. (2025). Assessment of the Efficacy of Antiemetic Medications in Reducing Postoperative Nausea and Vomiting among Patients Undergoing General/Regional Anesthesia: A Descriptive Cross-Sectional Study in Al Bayda, Libya. *Libyan Journal of Medical and Applied Sciences*, 140-144.

Bakr, R. A., & Othman, N. S. (2023). Assay of chloramphenicol in its pharmaceutical preparation (eye drop) via oxidation and bleaching color of neutral red dye. *Libyan Journal of Medical and Applied Sciences*, 31-40.

Elbarsha, A. M., Amer, S. E. A., & El Sahly, R. A. M. (2024). Knowledge regarding *H. pylori* management among hospital doctors in Benghazi, Libya. *Libyan Journal of Medical and Applied Sciences*, 38-44.

Elwalid, M. S., Elbeshti, R. T., & El-Ajnaif, S. M. (2025). Interactive effect of salinity and temperature on *Artemia* cyst hatching percentage. *Libyan Journal of Medical and Applied Sciences*, 1-7.

Eshlak, M., Elzain, E., Shalouf, M., & Salim, F. (2025). Assessment and correlation of antimicrobial resistance and prostate-specific antigen levels in prostatitis. *Libyan Journal of Medical and Applied Sciences*, 86-93.

Farag, K. A., Asselhab, M. A., Binsoud, B. M., & Abobaker, Z. M. (2025). Performance Comparison of Traditional Bootstrap and Bias-Corrected and Accelerated Methods in Constructing Confidence Intervals for Non-Normal Data: A Simulation Study. *Libyan Journal of Medical and Applied Sciences*, 115-120.

Gomaa, L. H., Gomaa, M. S., & Alhadad, A. H. (2024). Effect of using azithromycin and sodium stibogluconate in the treatment of cutaneous leishmaniasis. *Libyan Journal of Medical and Applied Sciences*, 28-31.

Muthanna, F. M., Samad, A., Ibrahim, H. K., Al-Awkally, N. A. M., & Sabir, S. (2022). Cancer related anaemia (CRA): An overview of approach and treatment. *International Journal of Health Sciences*, (II), 2552-2558.

Ahmed, A. A., & Khalifa, H. A. M. Z. A. (2020). E-learning and COVID-19 (Six important pieces of advice for teachers and academic teaching staff). *Eur Acad Res*, 8(2), 1216-1222.

Hamouda, E. A. F. (2025). Cardioprotective impact of aqueous *Saussurea lappa* root extract in female rats treated with tamoxifen. *Libyan Journal of Medical and Applied Sciences*, 72–78.

Zidan, K. R., & Aboukhadeer, R. A. (2025). The Impact of Noise in Industrial Work Environments A Field Study at Mellitah Oil & Gas. *Libyan Journal of Medical and Applied Sciences*, 33-41.

El-Sharif, F. E., Al-Qat, A. A. Q. M., & Moawi, A. I. (2025). A study of the effect of temperature on the structural properties of zinc oxide (ZnO) thin films. *Libyan Journal of Medical and Applied Sciences*, 39–47.

Bnnaser, M. N. A. (2025). The risks of urban sprawl on Wadi channels: A case study of Wadi Al-Ghorab in the city of Zintan, Libya. *Libyan Journal of Medical and Applied Sciences*, 39–52.

Aebeedat, A. M., Hendi, H. A., & Mustafa, A. A. (2025). The effect of foliar and soil application of urea fertilizer on the growth of the vegetative total of Nalta Jute (*Corchorus olitorius*). *Libyan Journal of Medical and Applied Sciences*, 23–29.

Farag, K. A., Asselhab, M. A., Binsoud, B. M., & Abobaker, Z. M. (2025). Performance Comparison

of Traditional Bootstrap and Bias-Corrected and Accelerated Methods in Constructing Confidence Intervals for Non-Normal Data: A Simulation Study. *Libyan Journal of Medical and Applied Sciences*, 115-120.

Ghania, A. A. A., Elbeshti, H. T., & Elwalid, M. S. (2025). Evaluation of Element Concentrations in Selected Economic Marine Fish Species in Tripoli, Libya. *Libyan Journal of Medical and Applied Sciences*, 17-25.

Wal, P., Saed, A., Almahtout, A. M., & Ahmed, S. A. (2023). A multidisciplinary exploration of diseases, treatments, and impact, from cancer-related anemia to pandemics and therapeutics. *Libyan Journal of Medical and Applied Sciences*, 14-30.

Khan, M. S., Khan, M. T. S., Ayub, A., Aslam, A., Basit, A., Hamza, M., & Khalifa, H. (2022). Effect of Covid 19 on Poultry Industry. *African Journal of Advanced Pure and Applied Sciences (AJAPAS)*, 23-25.

Ibrahim, H. K., Ahseen, N. A., Ahmed, T. I., Ahseen, N. A., Al-Awkally, N. A. M., & Yousuf, A. (2022). Evaluation of dexamethasone effects in COVID-19 treatment. *International journal of health sciences*, 6(S1), 546-554.